Biocon shares rebounded after the company announced a ₹4,500 crore Qualified Institutional Placement (QIP) to ease debt. SEBI registered analyst Ketan Mittal says the move is long-term positive but warns of short-term risks, including potential US pharma tariffs. HSBC cut its target to ₹390. Scaling up new biosimilars remains key to growth, he added.